Keith Regnante

KROS

Keith Regnante serves as CHIEF FINANCIAL OFFICER at Keros Therapeutics, Inc. (KROS). This page tracks their complete SEC Form 4 insider trading history including stock purchases and sales.

Total Buys

0 trades

$0.00

Total Sells

3 trades

$3.75M

Net Position

Net Seller

$3.75M

Companies Traded

KROS

Active Period

Jun 2023 – Feb 2026

3 total trades

Most Recent

Sell KROS

Feb 18, 2026 · $77.5K

Keith Regnante's Insider Trading at Keros Therapeutics, Inc. (KROS)

Buys

0 · $0.00

Sells

3 · $3.75M

Total Shares Bought

Total Shares Sold

84,739

KROS Price Chart

Loading chart...

Date	Type	Shares	Avg Price	Value	Shares After
Feb 18, 2026	Sell	4,739	$16.35	$77.5K	0
Jan 8, 2024	Sell	40,000	$45.29	$1.81M	0
Jun 12, 2023	Sell	40,000	$46.61	$1.86M	4,007

Related Insiders

BIENAIME JEAN JACQUES

director

KROSBuy · Apr 17, 2026

Jasbir Seehra

CHIEF EXECUTIVE OFFICER

KROSSell · Feb 19, 2026

Esther Cho

SVP, General Counsel

KROSSell · Feb 18, 2026

Lorena Raquel Lerner

Chief Science Officer

KROSSell · Feb 18, 2026

Pontifax Management 4 G.P. (2015) Ltd.

10% Owner

KROSSell · Oct 17, 2025

ADAR1 Capital Management, LLC

10% Owner

KROSSell · Oct 15, 2025

Explore More Insider Trading Data

KROS Insider Trading Activity

View all insider trades at Keros Therapeutics, Inc.

Healthcare Sector Insider Trades

See insider activity across healthcare stocks

Latest Insider Buys

Most recent insider purchases across all stocks

CEO Stock Purchases

Track CEO buying activity